Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
Date:11/6/2009

NEW YORK, Nov. 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Tuesday, November 10, 2009 at 8:30 a.m. EST to discuss the third quarter 2009 financial results and business outlook for the remainder of 2009. Ron Bentsur, Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing the Company's financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
2. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
3. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
4. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Fla., March 22, 2011 GeNO LLC ( ... company, today announced commencement of  the PHiano Study: ... of Pulmonary Hypertension in patients with Pulmonary Arterial ... Pulmonary Fibrosis (PH-IPF) using Inhaled NITROSYL™ nitric oxide ...
... Dry, dull skin can get you down in the ... professor and chair of the department of dermatology at Wake ... AmLactin® twice a day, seven days a week to get ... clinically proven alpha-hydroxy acid, 12% lactic acid, to gently exfoliate ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3Does Your Skin Need Therapy? 2Does Your Skin Need Therapy? 3
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... to find a colored ribbon representing a disease. A pink ... color ribbon does one think of with lung cancer?, Although ... suffering from the disease, black may be the only one ... lung cancer patients, primarily smokers between the ages of 51 ... stigma often felt by these patients, the emotional toll it ...
(Date:4/17/2014)... of Canadians surveyed said they would participate in public ... of genetic conditions, only 80 per cent said they ... sequence their newborns, genomes.,Most newborns in North America have ... two of life in which a tiny amount of ... about five to 54 conditions, depending on the state ...
(Date:4/16/2014)... , STANFORD, Calif. Consider the marvel of the embryo. ... shape and function as they multiply to become the cells ... tissues of the body. , Now, in a feat of ... the complex genetic coding that allows embryonic cells to proliferate ...
(Date:4/16/2014)... fertility treatments are the leading cause of increases in ... of premature birth, these results are not inevitable, concludes ... . The article identifies six changes in policy and ... and prematurity, including expanding insurance coverage for in vitro ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... Transcept,Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, ... 2008 Merrill Lynch Global,Pharmaceutical, Biotechnology and Medical Device ... City on Tuesday, February 5, 2008 at 8:40 ... Pharmaceuticals, Inc. is a specialty pharmaceutical company,deriving significant ...
... Feel Their Overall Health Affects Their,Recovery from Schizophrenia, ... Health,America of San Diego today released results of ... in mental health settings from the,perspective of both ... both groups are aware of actions to improve ...
... Baby Products, With Information, on the Best Baby Products and Easy-To-Follow ... ... Well, NORCROSS, Georgia, January 29 BabySupply.Info, has,launched today ... opportunity to save time and,money with a shopping comparison engine for baby ...
... Cause To Support Stefanie LaRue and Her Fight to,Live, ... cancer survivor Stefanie LaRue, known nationally as the "Breast,Cancer ... breast,cancer, is being honored at a benefit concert on ... at 2701 N. Sepulveda Blvd., Los,Angeles, CA. The event, ...
... billion -- Diluted earnings per share from continuing operations increase 16,percent ... ... -- Full year Non-GAAP EPS now expected to be $3.75 ... contract, DUBLIN, Ohio, Jan. 29 Cardinal Health, a,global provider of ...
... CHICAGO, Jan. 29 Medifacts Systems, Inc. announces ... genetic test patent to Mayo,Clinic. The patented test ... of blood-related disorders. The patent is the invention ... Vicksburg, Mississippi who,was educated at Xavier University in ...
Cached Medicine News:Health News:Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 4Health News:BabySupply.Info Announces Launch of Website for New Parents 2Health News:32-Year-Old Breast Cancer Survivor, Fashion Model Featured in Benefit Concert 'Music of the Light' at Skirball Cultural Center 2Health News:32-Year-Old Breast Cancer Survivor, Fashion Model Featured in Benefit Concert 'Music of the Light' at Skirball Cultural Center 3Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 2Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 3Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 4Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 5Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 6Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 7Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 8Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 9Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 10Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 11Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 12Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 13Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 14Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 15Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 16Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 17Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 18Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 19Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 20Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 21Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 22Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 23Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 24Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 25Health News:Cardinal Health Reports Second Quarter Results, Revises EPS Outlook 26Health News:Medifacts Systems, Inc. Grants Exclusive License for Genetic Test Patent to Mayo Clinic 2Health News:Medifacts Systems, Inc. Grants Exclusive License for Genetic Test Patent to Mayo Clinic 3